PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis.

Analysis of both the ‘all animals’ (Figure 9 A) and the ‘early CRP onset’ subgroup (Figure 9 B) showed a dose dependent reduction in inflammation, cartilage damage and bone damage that was highly significant for animals treated with 100 mg/kg.

also in 132,142 other papers